U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)

PRINCETON, N.J.--(BUSINESS WIRE) December 15, 2021 -- Bristol Myers Squibb (NYSE:BMY) today announced that Orencia (abatacept) was approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis, or prevention, of acute graft...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news